Lupin, a leading pharmaceutical company, has announced its collaboration with Honeywell to introduce an eco-conscious innovation in respiratory care. The initiative aims to incorporate Honeywell’s Solstice® Air (HFO-1234ze(E) cGMP) propellant into the next generation of inhalers for asthma and COPD patients. This propellant offers a sustainable alternative to conventional hydrofluorocarbon (HFC)-based options, significantly lowering greenhouse gas emissions—by up to 99.9%.

Through this partnership, Lupin aspires to be the first Indian pharmaceutical firm to adopt Solstice Air at scale in pressurized metered-dose inhalers (pMDIs). The use of this non-flammable, low-global-warming-potential (GWP) propellant represents a critical step in advancing environmentally responsible healthcare solutions without compromising treatment efficacy.

The agreement is still pending final documentation and mutual approval between both parties.

Vinita Gupta, CEO of Lupin, emphasized that this collaboration aligns with the company’s mission to offer top-quality treatments while contributing to a greener future. She highlighted that integrating Solstice Air not only supports effective respiratory care but also reduces the environmental footprint of medical treatments.

Echoing this sentiment, Ashish Modi, President of Honeywell India, noted that Solstice Air plays a pivotal role in enabling safe and efficient inhalers while supporting global carbon reduction efforts. He added that Honeywell remains committed to developing technologies that enhance both healthcare outcomes and sustainability practices across the industry.